 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...891892893894895896897898899900901...910911» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2013
P2, N=25, Recruiting, Sponsor: Drexel University
Active, not recruiting --> Recruiting
- | Vectibix (panitumumab) / Amgen
Enrollment closed: Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer (clinicaltrials.gov) - Feb 18, 2013
P2, N=33, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed: Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA) (clinicaltrials.gov) - Feb 18, 2013
P2, N=60, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed: PLANET: Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (clinicaltrials.gov) - Feb 18, 2013
P2, N=80, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Repatha (evolocumab) / Amgen, Astellas
Trial completion: GAUSS: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (clinicaltrials.gov) - Feb 18, 2013
P2, N=160, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Repatha (evolocumab) / Amgen, Astellas
Trial completion: RUTHERFORD: Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study (clinicaltrials.gov) - Feb 18, 2013
P2, N=168, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Prolia (denosumab) / Amgen
Enrollment open: Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2013
P3, N=1520, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Ongoing --> Recruiting
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Neulasta (pegfilgrastim) / Roche
Trial completion: Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer (clinicaltrials.gov) - Feb 14, 2013
P2, N=109, Completed, Sponsor: Harold J. Burstein, MD, PhD
Ongoing --> Recruiting Active, not recruiting --> Completed
- | conatumumab (AMG 655) / Amgen
Enrollment change: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed N=30 --> 12
- ||| Vectibix (panitumumab) / Amgen
IO biomarker: Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=450, Enrolling by invitation, Sponsor: Amgen
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: RELOADET: An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial (clinicaltrials.gov) - Feb 13, 2013
P4, N=85, Completed, Sponsor: Pfizer
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
New P4 trial: STARA: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 13, 2013
P4, N=400, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- | rilotumumab (AMG 102) / Amgen
New P1 trial, Metastases: Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ (clinicaltrials.gov) - Feb 13, 2013
P1, N=21, Recruiting, Sponsor: Amgen
- | conatumumab (AMG 655) / Amgen
Enrollment open: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
N=30 --> 12 Active, not recruiting --> Recruiting
- efruxifermin (AKR-001) / Akero Therap
Trial termination: Single Ascending Dose Trial in Patients With Type 2 Diabetes (clinicaltrials.gov) - Feb 12, 2013
P1, N=47, Terminated, Sponsor: Amgen
Active, not recruiting --> Recruiting Recruiting --> Terminated; Decision by Sponsor
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Trial completion: Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2013
P1, N=18, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Terminated; Decision by Sponsor Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: STEMPAD: Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (clinicaltrials.gov) - Feb 11, 2013
P3, N=8, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=60 --> 8
- | lenalidomide / Generic mfg.
New P2 trial, IO biomarker: FMG-MM02: First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02 (clinicaltrials.gov) - Feb 11, 2013
P2, N=80, Recruiting, Sponsor: Kuopio University Hospital
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment open: Busulfan and Cyclophosphamide Followed By ALLO BMT (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=30, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 8 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: STEMPAD: Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (clinicaltrials.gov) - Feb 11, 2013
P3, N=8, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- carboplatin / Generic mfg., cyclophosphamide / Generic mfg., amifostine / Generic mfg.
Enrollment change: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=11, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed N=28 --> 11
- |||||||||| Parsabiv (etelcalcetide) / Amgen
New P3 trial: Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis (clinicaltrials.gov) - Feb 7, 2013
P3, N=515, Active, not recruiting, Sponsor: Amgen
- | ivabradine / Generic mfg.
New P2 trial: Effect of ivabradine versus placebo on cardiac function and on capacity to perform exercise in patients suffering from diastolic heart failure. (EUDRACT) - Feb 7, 2013
P2, N=400, Ongoing, Sponsor: Institut de Recherches Internationales Servier
- carboplatin / Generic mfg., cyclophosphamide / Generic mfg., amifostine / Generic mfg.
Trial completion: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=11, Completed, Sponsor: University of Chicago
N=28 --> 11 Active, not recruiting --> Completed
- Stivarga (regorafenib) / Bayer
New P3 trial, Metastases: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (clinicaltrials.gov) - Feb 6, 2013
P3, N=0, Withdrawn, Sponsor: Asan Medical Center
- ||||| omecamtiv mecarbil (AMG 423) / Amgen, Servier
New P2 trial: COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (clinicaltrials.gov) - Feb 6, 2013
P2, N=570, Recruiting, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Starasid (cytarabine ocfosfate) / Nippon Kayaku
New P1/2 trial: Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 6, 2013
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| litronesib (KF 89617) / Kyowa Kirin, Eli Lilly
Trial completion: A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Feb 6, 2013
P2, N=250, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=19, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial initiation date: Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa (clinicaltrials.gov) - Feb 5, 2013
P2, N=192, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Initiation date: May 2005 --> Aug 2005
- Enrollment change: Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin (clinicaltrials.gov) - Feb 5, 2013
P1/2, N=26, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: May 2005 --> Aug 2005 N=68 --> 26
- || ivabradine / Generic mfg.
New P3 trial: Effects of ivabradine on atheroma plaque in patients with coronary artery disease (EUDRACT) - Feb 5, 2013
P3, N=500, Ongoing, Sponsor: Institut de Recherches Internationales Servier`Laboratorios Servier S.L.
- |||||||||| Parsabiv (etelcalcetide) / Amgen
New P3 trial: Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis (clinicaltrials.gov) - Feb 5, 2013
P3, N=1120, Recruiting, Sponsor: Amgen
- |||||||||| Parsabiv (etelcalcetide) / Amgen
New P3 trial: Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis (clinicaltrials.gov) - Feb 5, 2013
P3, N=508, Active, not recruiting, Sponsor: Amgen
- Vectibix (panitumumab) / Amgen
Enrollment closed: Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma (clinicaltrials.gov) - Feb 5, 2013
P2, N=45, Active, not recruiting, Sponsor: University of Pennsylvania
N=68 --> 26 Recruiting --> Active, not recruiting
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (clinicaltrials.gov) - Feb 5, 2013
P3, N=127, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin (clinicaltrials.gov) - Feb 5, 2013
P1/2, N=26, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Trial completion: KRAS Wild-type Metastatic Colorectal Cancer Trial (clinicaltrials.gov) - Feb 4, 2013
P1, N=21, Completed, Sponsor: University of Utah
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
New P2 trial: Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov) - Feb 3, 2013
P2, N=155, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Tirazone (tirapazamine) / Teclison, SRI International
Trial completion: Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors (clinicaltrials.gov) - Feb 3, 2013
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- docetaxel / Generic mfg.
Trial completion: Docetaxel in Treating Children With Recurrent Solid Tumors (clinicaltrials.gov) - Feb 3, 2013
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate (clinicaltrials.gov) - Jan 31, 2013
P4, N=120, Recruiting, Sponsor: Pfizer
- ||| Avastin (bevacizumab) / Roche, Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Jan 31, 2013
P2, N=104, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Trial termination, Combination therapy, Metastases: Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 30, 2013
P1/2, N=46, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated; Administratively complete.
- | Vectibix (panitumumab) / Amgen
Enrollment change: Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer (clinicaltrials.gov) - Jan 30, 2013
P2, N=30, Completed, Sponsor: University of Rochester
Completed --> Terminated; Administratively complete. N=15 --> 30
- |||| Evrenzo (roxadustat) / FibroGen
Trial completion: Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China (clinicaltrials.gov) - Jan 30, 2013
P2, N=96, Completed, Sponsor: FibroGen
N=15 --> 30 Recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, HEOR, Real-world evidence, Real-world: Characterize Patients With Moderately Active Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=1754, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- | Vectibix (panitumumab) / Amgen
Trial completion: Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer (clinicaltrials.gov) - Jan 30, 2013
P2, N=30, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Completed
- | YPEG-filgrastim (YPEG-rhG-CSF) / Xiamen Amoytop Biotech
Trial completion: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients (clinicaltrials.gov) - Jan 30, 2013
P1, N=30, Completed, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 30, 2013
P2, N=156, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed